CompletedNCT04414930
This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- University of California, San Diego
- Condition
- Schizophrenia
CompletedNCT02627716
This study exists to compare options and see whether questionnaires and follow-up reports offers something meaningfully different. Researchers are trying to understand whether questionnaires and follow-up reports can better prevent setbacks and support longer-term stability.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- France
- Sponsor
- University Hospital, Lille
- Condition
- Schizophrenia
CompletedNCT05664594
This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 15 Years to 45 Years
- Countries
- United States
- Sponsor
- University of Minnesota
- Condition
- Schizophrenia
CompletedNCT04846881
This study exists to learn from real-world information that can show how the medication Iclepertin fits into care. Researchers are trying to understand whether the medication Iclepertin can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 50 Years
- Countries
- Argentina, Brazil, Chile, Croatia, France, Hungary, Japan, Malaysia, Netherlands, Poland, Romania, Serbia, Singapore, Slovakia, South Korea, Spain, Ukraine, United States
- Sponsor
- Boehringer Ingelheim
- Condition
- Schizophrenia
CompletedNCT05414058
This study exists to see whether a medication treatment is workable and worth testing more broadly. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- Canada
- Sponsor
- The Royal Ottawa Mental Health Centre
- Condition
- Schizophrenia
CompletedNCT05741528
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- Schizophrenia
CompletedNCT05628103
This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Condition
- Schizophrenia
CompletedNCT01964404
This study exists to see whether smoking support or smoking-related treatment is workable and worth testing more broadly. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Condition
- Schizophrenia
WithdrawnNCT05939765
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Switzerland
- Sponsor
- Psychiatric University Hospital, Zurich
- Condition
- Schizophrenia
CompletedNCT07268430
This study exists to better understand the safety of the medication Long-Acting and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication Long-Acting in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- China
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Condition
- Schizophrenia
CompletedNCT05480046
This study exists to understand whether the medication Risperidone is both safe enough and useful enough to take further. Researchers are trying to understand whether the medication Risperidone can better prevent setbacks and support longer-term stability.
SchizophreniaOtherOver 18 Years
- Countries
- Germany, Italy, Portugal, Spain, United Kingdom
- Sponsor
- Rovi Pharmaceuticals Laboratories
- Condition
- Schizophrenia
CompletedNCT07266792
This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.
SchizophreniaOtherFrom 45 Years to 65 Years
- Countries
- India
- Sponsor
- Humanis Saglık Anonim Sirketi
- Condition
- Schizophrenia
CompletedNCT06136390
This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 75 Years
- Countries
- Germany
- Sponsor
- Charite University, Berlin, Germany
- Condition
- Schizophrenia
CompletedNCT06236451
This study exists to learn from real-world information that can show how a medication treatment fits into care. Researchers are trying to understand whether a medication treatment can better support energy, concentration, and everyday functioning.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- India
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Condition
- Schizophrenia
CompletedNCT04147897
This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand what helps a digital app or remote support tool stay useful, realistic, and easier to follow over time.
SchizophreniaOtherFrom 18 Years to 100 Years
- Countries
- United States
- Sponsor
- University of Washington
- Condition
- Schizophrenia
CompletedNCT06061952
This study exists to see whether questionnaires and follow-up reports is workable and worth testing more broadly. Researchers are trying to understand whether questionnaires and follow-up reports can make support easier to access outside standard clinic visits.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- University Hospitals Cleveland Medical Center
- Condition
- Schizophrenia
CompletedNCT04779177
This study exists to better understand the safety of this type of care and how manageable it feels in practice. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.
SchizophreniaOtherFrom 13 Years to 17 Years
- Countries
- United States
- Sponsor
- Intra-Cellular Therapies, Inc.
- Condition
- Schizophrenia
CompletedNCT04846868
This study exists to learn from real-world information that can show how the medication Iclepertin fits into care. Researchers are trying to understand whether the medication Iclepertin can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 50 Years
- Countries
- Australia, Brazil, Canada, China, Colombia, Germany, Greece, Italy, Japan, Mexico, New Zealand, Norway, Philippines, Poland, Sweden, Turkey, United States
- Sponsor
- Boehringer Ingelheim
- Condition
- Schizophrenia
CompletedNCT04317807
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 16 Years to 40 Years
- Countries
- United States
- Sponsor
- NYU Langone Health
- Condition
- Schizophrenia
CompletedNCT05227703
This study exists to compare options and see whether the medication CVL-231 offers something meaningfully different. Researchers are trying to understand whether the medication CVL-231 can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Bulgaria, Hungary, United States
- Sponsor
- AbbVie
- Condition
- Schizophrenia
CompletedNCT06179108
This study exists to compare options and see whether the medication LB-102 offers something meaningfully different. Researchers are trying to understand how people respond to the medication LB-102 in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- LB Pharmaceuticals Inc.
- Condition
- Schizophrenia
TerminatedNCT05368558
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Japan, Taiwan
- Sponsor
- AbbVie
- Condition
- Schizophrenia
CompletedNCT05838625
This study exists to see whether the medication Two can play a useful role in care. Researchers are trying to understand whether the medication Two can make support easier to access outside standard clinic visits.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- Click Therapeutics, Inc.
- Condition
- Schizophrenia
CompletedNCT06067984
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- Click Therapeutics, Inc.
- Condition
- Schizophrenia
CompletedNCT04457310
This study exists to understand what helps blood tests and biological markers work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 45 Years
- Countries
- United States
- Sponsor
- Yale University
- Condition
- Schizophrenia